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Cushing's Disease, a Pituitary Disorder
A hypothesis
M. Saeed Zafar, M D * and Raymond C, Mellinger, M D *

At present, Cushing's disease Is believed to be due to
Inappropriate secretion of adrenocorticotropic
hormone
(ACTH). Associated abnormalities such as disturbed sleep
pattern, growth hormone secretion, depressed thyroid hormone levels, and gonadal function are considered by some
as manifestations of a generalized central nervous system
disturbance, with abnormal ACTH secretion as one of the
components. Recognition of microadenomata in Increasing numbers of patients with Cushing's disease, the reversal
of hypothalamic abnormalities after adenomectomy, and

correction of hypercortisolemia all suggest that the central
nervous system disturbances result from Cortisol excess. We
hypothesize that the basic abnormality in Cushing's disease is the development of resistance to Cortisol at the level
of corticotrophs, due either to abnormal Cortisol receptors
or to a postreceptor defect. An increasing number of these
abnormal corticotrophs result in the development of hypercortisolemia subsequent to inappropriately elevated ACTH
levels.

l i v e r since Harvey Cushing described the syndrome that
commonly bears his name, controversy has surrounded the
nature of the central abnormality underlying its pathogenesis. Most early observers considered that the adrenal
or the pituitary was the primary site of the disturbed function. Cushing believed that pituitary basophilism was essential to the disorder. The demonstration of Crookes'
changes in the pituitary and remissions achieved in some
patients with pituitary irradiation were interpreted as evidence for a primary pituitary abnormality, while the failure
to achieve a cure in all subjects after pituitary irradiation
seemed to support the concept of a primary adrenal disorder. Subsequent inability to demonstrate elevated ACTH
levels seemed to weaken the hypothesis of primary pituitary hyperfunction, despite the demonstration of adrenal
hyperresponsiveness to exogenous ACTH. With better understanding of pituitary-adrenal physiology and the application of sensitive radioimmunoassay to the study of
pituitary and adrenal function, this issue has been clarified.
We now recognize that adrenal hyperfunction in Cushing's
syndrome can be due to adrenal autonomy (adenoma,
carcinoma or micronodular cortical hyperplasia) or to excessive ACTH. The disorder described by Cushing is cer-

tainly caused by excessive or inappropriate secretion of
pituitary ACTH.
Even with this acceptance, controversy persists. Debate has
shifted to the problem of whether the pituitary or the
controlling central nervous system is the site of the central
abnormality. Rather than being the independent "master
gland" o f t h e endocrine system, the pituitary is itself controlled by m u l t i p l e h y p o t h a l a m i c factors and neurotransmitters. Although corticotropin-releasing factor (CRF)
has not been isolated and identified per se, its essential role
in the releaseof pituitary ACTH is undisputed. Moreover, it
has been shown that the neurotransmitters serotonin and
acetylcholine stimulate ACTH release, while noradrenaline
and dopamine exert a suppressive influence, possibly
through the mediation of CRF (1). Based on evidence that
Cushing's disease is characterized by multiple abnormalities of the cyclic function known to be controlled by
the hypothalamus, e.g., loss of normal diurnal variation in
ACTH release, disturbed sleep pattern, disordered secretion of growth hormone (GH), and disturbances of the
menstrual cycle, Kreiger proposed that the disorder itself is
caused by abnormal function ofthe brain (2). On the other
hand, the presence of pituitary microadenomas in an increasing number of cases of the disease and its frequently
reported cure by pituitary adenomectomy suggest that the
primary abnormality resides in the hypophysis after all
(3-7). The following evaluation of the evidence also supports the concept that the hypothalamic abnormalities
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either result from Cortisol excess or are produced by a
primary pituitary abnormality.

or of the pituitary tumor rather than a part of any CNS
abnormality.

Diurnal variation of corticotropin

Gonadal function

The secretion of ACTH in normal individuals has a characteristic diurnal rhythm which is controlled by hypothalamic neurosecretory activity and modified by multiple
factors, most importantly Cortisol. Lesions of the anterior
hypothalamus will abolish the circadian ACTH rhythm
without affecting characteristic responses to most stresses.
Serotonin is known to be involved in the hypothalamic
controlling mechanism, and drugs which impair its action
prevent daily fluctuations in Cortisol levels (1). Because loss
of diurnal secretory rhythm is one of the most frequent
pathophysiologic features of Cushing's disease, a primary
central nervous system disorder may reasonably be postulated as the fundamental etiologic factor. However, the
documented recovery o f t h e circadian ACTH rhythm after
hypophyseal adenomectomy suggests that the pituitary
tumor is the central abnormality (7). Loss of circadian
rhythm either represents unresponsiveness of the pituitary
adenoma, or the sustained hypercortisolemia suppresses
the stimulus normally responsible for early morning ACTH
release.

Amenorrhea and disturbed gonadal function is a fairly
constant accompaniment of Cushing's disease. This abnormality is also not unique to any one etiologic type of
hypercortisolism, and many pathogenetic mechanisms
may be involved. In patients with pituitary tumors, diminished gonadotropin secretion may be due to encroachment
by the adenoma. In women with Cushing's disease, the
hyperplastic adrenal gland may secrete testosterone in
amounts sufficient to affect the menstrual cycle, while in
men with Cushing's syndrome, the glucocorticoids lower
testosterone by directly affecting testicular secretion. These
changes have been reversed both by adrenal adenomectomy and by removal of bilateral hyperplastic adrenals.
Accordingly abnormal gonadal function results from excessive secretions of the adrenal gland, and not as a
primary disorder of hypothalamic cycles (10-12).
Thyroid function
Since thyroid hormone levels in patients with Cushing's
disease are sometimes low without correspondingly elevated values for thyroid stimulating hormone (TSH), disturbed h y p o t h a l a m i c f u n c t i o n has been i m p l i c a t e d .
Although these effects could be attributed to a spaceoccupying, ACTH-secreting pituitary adenoma, the complex interrelationship between glucocorticoids and the hypothalamic-pituitary-thyroid axis may well provide the
explanation. Cortisol replacement in patients with Addison's disease normalizes the mildly elevated levels of TSH
which have been observed prior to therapy. Pharmacological doses of glucocorticoids have been demonstrated to
lower the peripheral generation of T3, to decrease thyroidal
uptake and release of iodine, to lower serum TSH levels,
and to blunt the TSH response to submaximal doses of
thyrotropin-releasing hormone (TRH) (14-21). Furthermore,
in patients with Cushing's disease the TSH response to TRH
has been observed to return to normal after successful
treatment by pituitary implant of radioactive gold (18).
Logical interpretation of these findings is that the pituitarythyroid dysfunction occurring in Cushing's disease is an
effect of Cortisol excess.

Sleep dysfunction and growth hormone abnormalities
Patients with Cushing's disease have impaired slow wave
sleep (stages III and IV). Although these sleep disturbances
persist in patients who have attained "remission" after
pituitary irradiation, they are not present in totally adrenalectomized patients with Nelson's syndrome. The abnormality has also been demonstrated in patients with cortisolsecreting adrenal adenoma, and the abnormal sleep patterns become normal after the removal of the cortical
tumor (8).
Not unexpectedly, the dynamics of growth hormone (GH)
also are disturbed in patients with Cushing's syndrome, for
nocturnal release of GH does not occur in patients who
have abnormal slow wave sleep (8). Moreover, a blunted
response of G H secretion to insulin-induced hypoglycemia
has been demonstrated not only in patients with Cushing's
syndrome due to pituitary disease but also in those with
cort isol-sec ret ing adrenal adenoma. In the group of patients we reported, the GH response to hypoglycemia was
blunted only in those who had severe Cushing's disease or
a demonstrable pituitary tumor. In patientswith mild Cushing's disease, GH response to hypoglycemia was apparently normal. Moreover, the abnormalities reverted to
normal after reversal ofthe hypocortisolemia in all patients
except one with overt pituitary tumor (9). It is reasonable to
conclude that GH and sleep abnormalities in patients with
Cushing's disease are an effect either of hypercortisolemia

Prolactin
Generalized hypothalamic dysfunction, invoked as a cause
of Cushing's disease, would reasonably be associated with
elevated prolactin (PRL) levels. However, in most patients
studied the basal level of prolactin, as well as its response
to TRH, is normal (18-21). In a recent report, the PRL
response to TRH was normal in four of five cases of
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Cushing's disease, while in the fifth case, minimal elevation in basal PRL present fell to normal after pituitary
surgery (6). The evidence clearly does not suggest that a
primary disturbance o f t h e hypothalamus is present.

disease. After pituitary stalk section, the patient responded
to dexamethasone with partial suppression of plasma Cortisol levels and to metyrapone with increased levels. Similar responses had been observed before the stalk surgery
(23). Thus, we believe that the primary abnormality in the
pathogenesis of Cushing's disease resides in the pituitary
itself.

Discussion
Patientswith Cushing's disease have many hypothalamic
abnormalities, including sleep disturbances and deranged
control of anterior pituitary secretions. All can be attributed
either to the effect of a functioning pituitary tumor or to
pathophysiologic alterations secondary to elevated Cortisol
levels. This interpretation is strengthened by evidence that
the CNS abnormalities, including the disturbed diurnal
A C T H r h y t h m , are r e v e r s e d by h y p o p h y s e a l
adenomectomy.

A reasonable speculation is that a developing clone of
corticotrophs has reduced sensitivity to the suppressive
effect of Cortisol, possibly because of either a deficiency of
glucocorticoid receptors or a postreceptor abnormality.
These corticotrophs, less sensitive to Cortisol, may nevertheless respond to h y p o t h a l a m i c factors. The corticotrophs in Cushing's disease may even respond to
stimuli which do not normally activate ACTH-secreting
cells, e.g. TRH. With proliferation, these cells induce the
hypercortical state characteristic of Cushing's disease. The
elevated Cortisol levels inhibit secretion of ACTH by normal corticotrophs and, along with the excessive ACTH
itself, inhibit normal hypothalamic secretion of the CRF.
Impaired CRF secretion may explain the lack of Cortisol
response to hypoglycemia observed in this disorder. The
degree of resistance to Cortisol and the rate of proliferation
ofthe resistant clone determine the developmental tempo
ofthe physical manifestations and the size o f t h e pituitary
tumor. The exaggerated response to metyrapone, the development of sellar enlargement demonstrated by lateral
skull films (Nelson's syndrome) after bilateral adrenalectomy, and the increasing frequency with which these pituitary adenomas are demonstrated by modern radiologic
techniques in patients with Cushing's disease all provide
important support for the hypothesis.

Studies o f a recent patient with Cushing's disease illustrate
the concept (22). This patient had a large ACTH-secreting
pituitary tumor which could be only partially removed;
stalk section was performed at the time of the partial
hypophysectomy. Subsequently although the patient's 24hour urinary-free Cortisol was within normal limits, the
plasma Cortisol level was not suppressed by the overnight
1 mg dexamethasone test and failed to undergo diurnal
variation. When 8 mgs of dexamethasone were administered, the Cortisol level was partially suppressed. We
interpret these observations to indicate that in Cushing's
disease the lack of diurnal change in ACTH secretion is a
manifestation of the autonomous pituitary tumor and that
the suppressing effect of dexamethasone is definitely exerted at the level of the anterior pituitary. Liddle, et al
reported a similar observation in a woman with Cushing's
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